
Description

The present invention relates to 4(5)-substituted imidazole derivatives and their non-toxic salts, and their preparation and use.

FR—A—2542738 and J. Med. Chem 1984, 27(5) pp 570—6 describe various 2-substituted imidazole derivatives which have been found to act as α_2-antagonists.

The imidazole derivatives of this invention are new potent and selective α_2-receptor antagonists of the formula:



(I)

wherein X is $—CH_2—$, $—CH_2CH_2—$ or —O—, R_1 is H, alkyl of 1 to 4 carbon atoms, alkenyl of 2 to 4 carbon atoms, OCH_3 or OCH_2CH_3, R_2 is H, CH_3, CH_2CH_3, OCH_3 or OH, R_3 is H, CH_3, CH_2CH_3, OCH_3 or Hal, R_4 is H, CH_3, CH_2CH_3, OCH_3 or Hal, and Hal is halogen, and their non-toxic pharmaceutically acceptable acid addition salts.


The compounds of the formula (I) form acid addition salts with both organic and inorganic acids. They can thus form any pharmaceutically usable acid addition salts, as, for instance, chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates, ascorbates and the like.

The invention includes within its scope pharmaceutical compositions comprising at least one of the compounds of formula (1) or a non-toxic, pharmaceutically acceptable salt thereof, and a compatible pharmaceutically acceptable carrier therefor.

Adrenergic receptors are physiologically active binding sites which are specific to noradrenaline and adrenaline and located on the surface of the cell membrane. The adrenoceptors of the sympathetic nervous system have been classified into two different subtypes, namely alpha-(α) and beta-(β) receptors which can both be further divided into two subgroups, i.e. α_1 and α_2 as well as β_1 and β_2. Of these receptor types, B_1, B_2 and α_1 are mainly located postsynaptically on the surface of, e.g., smooth muscles and thus mediate, e.g., smooth muscle contraction or relaxation; whereas α_2 receptors are mainly located presynaptically on the terminals of noradrenergic nerves. If α_2 receptors are stimulated by noradrenaline under physiological conditions, noradrenaline release is blocked, i.e. there is a negative feed-back phenomenon.

As well as by noradrenaline itself, this negative feed-back phenomenon may be induced by certain synthetic α_2-agonists like detomidine (compound A) and some of its near derivatives. The primary pharmacodynamic effects of detomidine, e.g. sedation, have also been proved to be due to its ability to stimulate α_2-receptors (Virtanen et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry, suppl. 1983, p. 308).

The compounds of formula (I) have valuable properties as antagonists to sedatives and analgetics used in veterinary medicine. Such veterinary medicines include, e.g., detomidine (compound A) and near derivatives thereof.



Compound A

(detomidine)

Compound A has been disclosed in e.g. Eur. Pat. Appl. 24829.

Detomidine is used in veterinary medicine, especially in the handling of horses and cattle (pharmacological restraint), whereby the animal is sedated before investigation, treatment and difficult medical operations. Even a small surgical operation cannot be carried out without the use of a sedative agent.

When the treatment using detomidine has been completed, it is for practical reasons desirable to interrupt and restrain its effect by a specific antagonist or antidote. The animal can then immediately be transported away from the surgery, and expensive awakening rooms are not required. The ability of the animal to control its movements and co-ordination after awakening is improved. When animals are treated in cold surroundings this is absolutely necessary, because otherwise the animal will remain lying still for too long a time. When an awakening agent is used, the feeding of cattle can start more rapidly than otherwise. An interruption in feeding causes disturbances in production.

The use of an awakening agent in association with the use of detomidine saves time for the veterinarian as well as for the owner of the animal. The antidote makes practical the use of higher doses of detomidine, which induce a stronger analgetic effect. Thus, the safety of the treatment of big animals is increased. Without any awakening agent, detomidine cannot be used in some cases, as it is often not possible to wait until the animal has recovered from the influence of detomidine.


A selective α_2-antagonist may also be predicted to be of use in some diseases which are believed to be connected with deficiency of noradrenalin available in the postsynaptic adrenoceptors of the central and/or peripheral nervous system. These diseases include, e.g., endogenic depression and asthma.

Glucose and lipid metabolisms are regulated by an inhibitory mechanism involving α_2-receptors. Thus α_2-antagonists may be significant in the treatment of metabolic diseases like diabetes and obesity.


Presynaptic α_2-receptors also take part in platelet aggregation. It has been shown that α_2-agonists active and antagonists inhibit human platelet aggregation (Grand & Schutter, Nature 1979, 277, 659). Thus α_2-antagonists may be useful clinically in pathogenic states involving increasing aggregation, e.g. migraine. The acute effects of ergotamine, a classical compound against migraine, are regarded as being due to its α_1-agonist effect. Thus compounds with both antagonist effects of α_2-receptors and agonist effects of postsynaptic α_1-receptors may have great advantages in the acute and preventive treatment of migraine.

The compounds of the formula (I) can be prepared by the following processes:


A.



B.




wherein each of R_5, R_6, R_7 and R_8 is hydrogen, hydroxy, halogen, amino, —O-alkyl containing 1 to 7 carbon atoms, or





(wherein R_9 is an alkyl radical containing 1 to 7 carbon atoms or an aryl radical containing 6 to 10 carbon atoms); and wherein R_5 and R_7 can be combined to form a keto group, or R_6 and R_8 can be combined to form a keto group.

In process B, the following compounds can for example be used as starting materials:




,







,




and





A particularly convenient way to perform process B is the following (B1):






Another advantageous adaptation of process B is B2:







C.




wherein R_3 is a halogen atom and R_4 is H or both R_3 and R_4 are halogens.

D.






E.




wherein R is a benzyl group.

F.



G.



In process A the halogenation step can be performed by reaction with e.g. bromine in methylene chloride or diethyl ether with stirring at about 10°C.

In the second step the halogenated product and formamide are heated at 130—200°C for 3—8 hours.

The catalytic hydrogenation is performed in acidic water-ethanol mixture at about 70°C at normal or elevated pressure using e.g. Pd/C as catalyst.


In process B1 the first and second steps are performed in the same way as the corresponding steps in process A.

Process B2. The Grignard reaction is carried out in an ether, e.g. tetra-hydrofuran or diethyl ether, at room temperature.


The reduction step is performed with e.g. sodium borohydride in ethanol at room temperature. The reaction with formamide is carried out as in A and B1, namely by heating at 130—200°C for 3—8 hours.

Process C. The halogenation is carried out with e.g. bromine in acidified water at about 10°C.


The following compounds of formula I are of special value as α_2-antagonists:




Compound I
4(5)-(2,3-dihydro-1H-inden-2-yl)-imidazole




Compound II
4(5)-(2,3-dihydrobenzofuran-2-yl)imidazole




Compound III
4(5)-(5-bromo-2,3-dihydrobenzofuran-2-yl)imidazole




Compound IV
4(5)-(2,3-dihydro-5-methyl-1H-inden-2-yl)imidazole




Compound V
4(5)-(4-methyl-2,3-dihydro-1H-inden-2-yl)imidazole




Compound VI
4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole




Compound VII
4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole




Compound VIII
4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole




Compound IX
4(5)-(5-chloro-2,3-dihydro-1H-inden-2-yl)imidazole




Compound X
4(5)-(5-bromo-2,3-dihydro-1H-inden-2-yl)imidazole




Compound XI
4(5)-(2,3-dihydro-1-hydroxy-1H-inden-2-yl)imidazole




Compound XII
4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole




Compound XIII
4(5)-(4-chloro-2,3-dihydro-1H-inden-2-yl)imidazole




Compound XIV
4(5)-(4-bromo-2,3-dihydro-1H-inden-2-yl)imidazole




Compound XV
4(5)-(2,3-dihydro-2-ethyl-1H-inden-2-yl)imidazole



Compound XVI
4(5)-(2,3-dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole



Compound XVII
4(5)-(2,3-dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole



Compound XVIII
4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole

The pharmacological activity of the compounds of the present invention was determined as follows:

1. α_2-antagonism *in vitro*

α_2-antagonism was determined by means of isolated, electrically stimulated mouse vas deferens preparation (Marshall et al., Br. J. Pharmac. 62, 147, 151, 1978). In this model, α_2-agonist (detomidine) blocks electrically stimulated muscular contractions and the effect of the α_2-antagonist is seen by administering it prior to the agonist and by determining its pA_2 value. Known α_2-antagonists like yohimbine and rauwolscine were used as reference substances.

To obtain information also on the selectivity of the antagonist between α_1- and α_2-receptors, its ability to inhibit or stimulate α_1-receptors was determined by means of isolated anococcygeus muscle (rat). The reference substances were now phenylephrine, a known α_1-agonist, and prazosin, a known α_1-antagonist. To determine α-antagonism, muscular contraction was induced by phenylephrine and the pA_2 value of the studied compound was determined as above. α_1-agonist effect is presented as the pD_2 value (negative logarithm of the molar concentration of the compound producing 50 per cent of maximal contraction). Examples of the results are given in Table 1.

TABLE 1

	α_2-antagonism (pA_2 vs detomidine) mouse vas deferens	α_1-antagonism (pA_2 vs phenylephrine) rat anococcygeus	α_1-agonism (pD_2) rat anococcygeus
Compound I	8.8	—	6.5
Compound II	7.5	—	5.5
Compound III	6.2	—	4.5
Compound IV	7.7	—	6.5
Compound VI	8.7	—	6.5
Compound VII	7.6	—	6.0
Compound VIII	7.6	5.9	—
Compound XII	8.1	—	5.5
Compound XV	8.3	—	—
Compound XVII	6.6	—	—
Compound XVIII	7.7	—	6.0
Yohimbine	8.1	6.6	—
Rauwolscine	8.1	6.3	—
Prazosin	<5	9.0	—
Phenylephrine	—	—	6.5

2. α_2-antagonism *in vivo*

The central α_2-blocking effect of the studied substances under *in vivo* conditions was studied using two methods. First, it is known that in the rat α_2-agonists induce dilatation of the pupil (mydriasis) which effect is transmitted via α_2-receptors of the central nervous system. In anaesthetized rat, a standard dose of detomidine was administered intravenously. Thereafter increasing doses of the studied antagonist were injected intravenously and the reversal of detomidine-induced mydriasis was followed. The ED_{50} value of the antagonist, i.e. the dose producing a 50 per cent reversal, was determined. Examples of the results of this test are presented in Table 2.

TABLE 2

Compound	ED_{50} (µg/kg iv)
I	3
II	70
III	320
IV	20
VI	100
VII	100
VIII	100
XII	3
XV	6
Yohimbine	200
Phentolamine	1000
Prazosin	>1000

α_2-antagonism in the central nervous system was secondly studied by following the ability of the antagonist to inhibit detomidine induced sedation in the mouse. This was done by measuring the increase of barbiturate sleeping time induced by detomidine. This effect of detomidine is known to be induced through α_2-receptor activation. The antagonist can be studied by administering it prior to detomidine. The results of the selected compounds are shown in Table 3.

TABLE 3

Effect of different antagonists (± per cent of controls) on detomidine (150 µg/kg ip) induced potentiation of the barbiturate sleeping time in mice

Dose mg/kg	Compound I	Compound II	yohimbine	prazosin
0.1	−20	−5	0	0
0.3	−60	−30	−18	0
1	−100	−60	−64	0
3	not measured	−70	−70	+16
10	not measured	−85	−100	+18

In the examples below, where ^1H and ^{13}C NMR spectrum shifts are presented, the NMR spectra w determined with a Bruker WB 80 DS apparatus using an internal tetramethylsilane standard, from wh the presented chemical shifts (δ, ppm) are tabulated. The letters s, d, t and m are used to indicate a sing doublet, triplet or multiplet, respectively. In the same connection, the number of hydrogen atoms is a stated. The compounds which are indicated as bases are tested in deuterium methanol, deuterium acet or deuterium chloroform, while the values for compounds which are indicated as hydrochlorides w determined in deuterium oxide or deuterium methanol. The mass spectra were determined with a Kra MS 80 Autoconsole apparatus. It is believed that "Kratos" is a registered Trade Mark in one or more of designated states.

Example 1


4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

The 1-(2,3-dihydro-1H-inden-2-yl)ethanone used as the starting material can be obtained according to the publication (Carlson, G. L. B., Quina, F. H., Zarnegar, B. M. and Whitten, D. G., *J. Am. Chem. Soc. 97* (1975) 347).

a) 2-Bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone

Bromine (6.8 g) is slowly added to a stirred solution of 1-(2,3-dihydro-1H-inden-2-yl)ethanone (6.8 g) in 200 ml of dry ether, while keeping the temperature at +10°C. The rate of the addition of bromine is controlled so that the colour due to one added portion of bromine has been discharged before another portion is added. When the addition is complete, the ethereal solution is washed four times with 3 M sodium carbonate solution, and is then washed three times with water. The ethereal solution is dried with anhydrous magnesium sulphate. After removal of the solvent the solid 2-bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone is obtained.

MS (*m/z*, % the relative intensity): 240 and 238 (8 and 12, $M^{+\cdot}$), 159 (47, M—Br), 145 (31, M—CH_2Br), 117 (73, M—$COCH_2Br$), 116 (78), 115 (100,

(100, )

b) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

A mixture of 2-bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone (9.4 g) and formamide (140 ml) is heated at 170—180°C for 4 hours. Then the reaction mixture is allowed to cool to ambient temperature and poured into ice-cold, dilute hydrochloric acid solution. The mixture is washed twice with toluene. Then the aqueous layer is made alkaline with ammonia and extracted several times with ethyl acetate. The combined organic layers are dried over anhydrous magnesium sulfate and evaporated to dryness under reduced pressure. The oily residue, which contains the crude product of 4(5)-(2,3-dihydro-1H-inden-2-yl)imidazole is purified by flash chromatography (solvent system: methylene chloride — methanol 9.5:0.5). The 4(5)-(2,3-dihydro-1H-inden-2-yl)imidazole thus obtained is converted to its hydrochloride salt. The base is dissolved in ethyl acetate. Dry hydrogen chloride in ethyl acetate is added. The hydrochloride is precipitated with dry ether.

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole hydrochloride:

MS: 184 (100 $M^{+\cdot}$), 183 (71, M—H), 169 (89, M—CH_3), 156 (32), 150 (10), 147 (12), 142 (17), 141 (10), 139 (18), 129 (20), 128 (24), 127 (15), 119 (12), 116 (23), 115 (36), 111 (10), 91 (25), 77 (8), 69 (20).

^{1}H NMR (80 MHz, MeOH-d_4): 2.93—3.83 (5H, m, H_2^1, H^2 and H_2^3), 7.08—7.27 (4H, m, aromatic), 7.35 (1H, dd, im-5(4)), 8.83 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): 36.80 (OFR d, C_2), 39.71 (2t, C_1 and C_3), 115.96 (d, im-5(4)), 125.32 (2d, aromatic), 127.86 (2d, aromatic), 134.85 (d, im-2), 138.76 (s, im-4(5)), 142.42 (2s, C_8 and C_9).

Example 2

4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole

a) 1-(Benzofuran-2-yl)-2-bromoethanone

Benzofuran-2-yl methyl ketone (20 g) is dissolved in 100 ml of methylene chloride and 3.2 ml of bromine in methylene chloride is added at 5—10°C. Then the reaction mixture is stirred at +15°C for 2 hours. Then it is washed with water, with diluted sodium bicarbonate solution and again with water. The organic phase is dried and evaporated to dryness to give crude 1-(benzofuran-2-yl)-2-bromoethanone.

b) 4(5)-(Benzofuran-2-yl)imidazole

The crude product from step a) (12,1 g) and formamide (60 ml) are combined and heated at 170°C for 5 hours. The reaction mixture is poured in water and concentrated hydrochloric acid added to make the mixture acidic. It is then washed with methylene chloride and the aqueous phase is made alkaline with sodium hydroxide. The product is extracted into methylene chloride which thereafter is washed with water, dried with sodium sulfate and evaporated to dryness. The residue consisting of crude product is converted to its hydrochloride salt in ethyl acetate. M.p. 229—235°C.

^{1}H NMR (80 MHz, D_2O): 4.96 (2H, s), 6.77 (1H, s), 7.16—7.49 (6H, m), 8.46 (1H, s).

c) 4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole

The product from step b) (5 g) is dissolved in water (60 ml) and ethanol (30 ml) and concentrated hydrochloric acid (9 ml) is added. Then the reaction mixture is hydrogenated at 60°C with 10% palladium on carbon as catalyst until no more hydrogen is consumed.

Then the catalyst is filtered and ethanol is distilled off. The aqueous solution is washed with methylene chloride and made alkaline with sodium hydroxide. The product is extracted into toluene. The toluene is

washed with water and evaporated. The residue is crystallized from toluene-isopropanol and is then converted to its hydrochloride salt in isopropanol-ether. The yield is 1.3 g, m.p. 177—178°C.

MS: 186 (46%), 185 (13%), 170 (15%), 169 (100%), 159 (5%), 158 (8%), 157 (7%), 146 (16%), 142 (43%), 131 (11%), 130 (20%), 103 (10%).

Example 3

4(5)-(5-Bromo-2,3-dihydrobenzofuran-2-yl)imidazole

4(5)-(2,3-dihydrobenzofuran-2-yl)imidazole (0.6 g) and water (8 ml) are combined. Concentrated hydrochloric acid is added until the solution is acidic. Bromine (0.52 g) is added dropwise at about 10°C and the mixture is stirred at this temperature for another half an hour. The precipitated product is filtered off and washed with water. The crude product is dissolved in warm water and the undissolved material filtered off. The filtrate is made alkaline with sodium hydroxide and the precipitate is filtered off. The product is converted to its hydrochloride salt in isopropanol-ether. The yield of 4-(5-bromo-2,3-dihydrobenzofuran-2-yl)imidazole hydrochloride is 0.4 g, m.p. 202—204°C. M.p. of the base is 187—188°C.

Example 4

cis-4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole

The *cis*-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid used as the starting material can be obtained according to the literature (for example Shadbolt, R. S., *J. Chem. Soc.* (C), (1970) 920).

a) *cis*-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid chloride

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid (52.6 g) is converted to its acid chloride by treatment with thionyl chloride (130 ml). Excess thionyl chloride is distilled off and the acid chloride is distilled, b.p. 86—89°C/0.45 mmHg. The yield is 47.9 g, 83%.

b) *cis*-1-(2,3-Dihydro-1-methyl-1H-inden-2-yl)ethanone

cis-1-(2,3-Dihydro-1-methyl-1H-inden-2-yl)ethanone is prepared by the treatment of *cis*-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid chloride with ethoxymagnesiummalonic acid ethyl ester in dry ether and thereafter by the treatment of sulfuric acid according to the publication (Reynolds, G. A. and Hauser, C. B., *Org. Synth. 30* (1957) 70). The yield is 92%.

cis-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

MS: 174 (31, $M^{+\cdot}$), 159 (71, M—CH_3), 131 (38, M—$COCH_3$), 130 (100), 129 (27), 128 (21), 116 (24), 115 (54), 91 (33), 43 (16, C^+OCH_3).

^{1}H NMR (80 MHz, $CDCl_3$): 1.36 (3H, d, J 6.67 Hz, >CHCH_3), 2.24 (3H, s, COCH_3), 2.79—3.64 (4H, m, H^1, H^2 and H_2^3 of the indane ring), 7.17 (4H, s, aromatic).


^{13}C NMR (20 MHz, $CDCl_3$): δ 19.60, 28.99, 34.80, 41.58, 61.05, 123.17, 124.13, 126.65, 126.71, 140.48, 146.38, 208.99.

c) 2-Bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone

Bromine in methylene chloride is slowly added to a stirred solution of *cis*-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone (34.8 g) in methylene chloride (835 ml), while keeping the temperature at +10°C. The reaction is followed by GLC. The first products are the isomers of 1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone and *cis*-2-bromo-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone. When the added amount of bromine is about 0.3 mol, only the final product, 2-bromo-1-(2-bromo-2,3-dihydrol-methyl-1H-inden-2-yl)ethanone is visible in the chromatogram and the mono bromo products cannot be seen in the chromatogram any more. The methylene chloride solution is washed with water, then several times with the diluted $NaHCO_3$ solution and finally with water. The solvent is dried with Na_2SO_4 and evaporated to dryness.

2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

MS of the isomer a: 334, 332, 330 (0.5, 1, 0.5, $M^{+\cdot}$), 253 and 251 (65 and 68, M—Br), 211 and 209 (1 and 1, M—$COCH_2Br$), 172 (11), 157 (28), 148 (26), 131 (15), 130 (80), 129 (93), 128 (79), 127 (30), 123 (22), 121 (23), 115 (100,

(100, )

102 (10), 95 (14), 93 (14), 77 (11).

MS of the isomer b: $M^{+\cdot}$ invisible, 253 (65), 251 (69), 209 (1), 211 (1), 172 (17), 157 (38), 143 (28), 131 (14), 130 (69), 129 (100), 128 (85), 127 (35), 123 (18), 121 (18), 115 (95), 102 (11), 95 (13), 93 (14), 77 (12).

cis-2-bromo-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

If the products are isolated, when 0.2 mol of bromine (instead of 0.3 mol) has been added, the following mixture of products is obtained: 1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone, *cis*-2-bromo-1-

(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone and 2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone. Also a little amount of the starting compound can be seen in the chromatogram.

MS: $M^{+\cdot}$ invisible, 173 (100, M—Br), 155 (12), 145 (26), 143 (10), 131 (31, M—$COCH_2Br$), 130 (16), 129 (29), 128 (26), 127 (14), 116 (29), 115 (59), 91 (28).

d) 4(5)-(3-Methyl-inden-2-yl)imidazole

2-Bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone (34.0 g) and formamide (520 ml) are combined and the mixture is heated with stirring at 170°C for about 3 hours. The reaction mixture is cooled, then poured into water, made acidic with hydrochloric acid and washed with methylene chloride. The aqueous layer is then made alkaline with sodium hydroxide and the mixture is extracted with ethyl acetate. The organic extracts are washed with water and dried and evaporated to dryness. The residue, which consists of the crude product, is converted to the hydrochloride salt in ethyl acetate. After the recrystallization of the hydrochloride from isopropanol-ethanol the yield of the product is 11.4 g, 48% (m.p. 265—268°C).

The hydrochloride salt of 4(5)-(3-methyl-inden-2-yl)imidazole:

MS: 196 (100, $M^{+\cdot}$), 195 (44, M—H), 181 (30, M—CH_3), 168 (10), 167 (10), 141 (12), 139 (9), 127 (12), 115 (10), 98 (8), 97 (9).

^{1}H NMR (80 MHz, MeOH-d_4): δ 2.34 (3H, t, ^{5}J 2.22 Hz, CH_3), 3.75 (2H, q, ^{5}J 2.22 Hz, >CH_2), 7.16—7.55 (4H, m, aromatic), 7.71 (1H, d, im-5(4)), 8.97 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): δ 12.10 (OFR q), 40.16 (t), 116.81 (d), 120.75 (d), 124.56 (d), 126.04 (s), 127.19 (d), 127.74 (d), 131.49 (s), 134.79 (d), 141.06 (s), 143.30 (s), 146.63 (s).

e) 4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole

The crude product of 4(5)-(3-methyl-inden-2-yl)imidazole (3.3 g) is dissolved in water (40 ml)-ethanol (20 ml)-concentrated hydrochloric acid (6 ml) solution. Then 0.33 g of 10% Pd/C is added and the mixture is stirred vigorously under a hydrogen atmosphere at about 60°C until no more hydrogen is consumed. The reaction mixture is then filtered and the filtrate is evaporated to a smaller volume. The acidic solution is washed with methylene chloride. The aqueous phase is then made alkaline and extracted with methylene chloride. The organic extracts are dried and evaporated to dryness. The crude *cis*-4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole is purified by converting it into the hydrochloride salt in acetone-ethyl acetate. The melting point of the hydrochloride is 192—194°C.

The hydrochloride salt of *cis*-4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole:

MS: 198 (100, $M^{+\cdot}$), 197 (27, M—H), 183 (78, M—CH_3), 170 (14), 169 (43), 156 (17), 154 (18), 142 (11), 130 (36), 129 (24), 128 (27), 127 (15), 117 (14), 116 (12), 115 (44), 91 (25), 82 (17), 81 (30), 77 (11).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.94 (3H, d, ^{3}J 7.01 Hz, CH_3), 3.23—4.03 (4H, m, H^1, H^2 and $H_2{}^3$), 7.19—7.25 (5H, m, aromatic and im-5(4)), 8.85 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, DMSO-d_6): δ 16.34 (OFR q), 34.41 (t), 39.23 (d), 41.95 (d), 115.73 (d), 123.66 (d), 124.08 (d), 126.50 (2d), 133.28 (d), 133.77 (s), 140.49 (s), 147.00 (s).

Example 5

cis-4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole

a) α-Acetyl-4-methylbenzenepropanoic acid ethyl ester

The starting material, α-acetyl-4-methylbenzenepropanoic acid ethyl ester can be prepared for example according to the publication by L. Borowiecki and A. Kazubski (*Pol. J. Chem. 52* (1978) 1447). Yield 60%, b.p. 120—150°C/0.15 mmHg.

α-Acetyl-4-methylbenzenepropanoic acid ethyl ester:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.20 (3H, t, J 7.18 Hz, CH_2CH_3), 2.17 (3H, s, CH_3CO or $ArCH_3$), 2.29 (3H, s, $ArCH_3$ or CH_3CO), 3.11 (2H, distorted d, J_{ab} 7.58 Hz, >$CHCH_2$—), 3.74 (1H, distorted t, J_{ab} 7.58 Hz, >$CHCH_2$—), 4.14 (2H, q, J 7.18 Hz, CH_2CH_3), 7.06 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 13.91, 20.88, 29.35, 33.56, 61.23, 61.35, 128.49 (2), 129.10 (2), 134.97, 136.00, 169.00, 202.15.

b) 1,6-Dimethyl-indene-2-carboxylic acid

The 3,5-dimethyl-indene-2-carboxylic acid can be prepared by the treatment of α-acetyl-4-methylbenzenepropanoic acid ethyl ester with sulfuric acid (Shadbolt, R. S., *J. Chem. Soc.* (C), (1970) 920). Recrystallization from ethanol, m.p. 174—182°C. Yield 59%.

3,5-dimethyl-indene-2-carboxylic acid:

^{1}H NMR (80 MHz, DMSO-d_6): δ 2.38 (3H, s, $ArCH_3$),

2.46 (3H, t, ^{5}J 2.39 Hz, $=C^1(CH_3)$—),

3.53 (2H, q, ^{5}J 2.39 Hz, CH_2), 6.68 (1H, broad s, COO*H*), 7.11—7.44 (3H, m, aromatic).

^{13}C NMR (20 MHz, DMSO-d_6): δ 11.95 (OFR q), 20.97 (q), 38.14 (t), 121.33 (d), 123.51 (d), 128.20 (d), 130.59 (s), 135.59 (s), 140.07 (s), 145.06 (s), 149.60 (s), 166.49 (s).

c) 3,5-Dimethyl-indene-2-carboxylic acid chloride

3,5-Dimethyl-indene-2-carboxylic acid (37.3 g) is converted to its acid chloride by treatment with thionyl chloride (580 ml). Excess thionyl chloride is distilled off. Yield 40.5 g, 99%.

d) 1-(3,5-Dimethyl-inden-2-yl)ethanone

1-(3,5-Dimethyl-inden-2-yl)ethanone is prepared by the same procedure as *cis*-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone in Example 4b. A mixture of dry ether and tetrahydrofuran is used as solvent. Yield 84%.

1-(3,5-Dimethyl-inden-2-yl)ethanone:

MS: 186 (68, $M^{+\cdot}$), 171 (35, M—CH_3), 144 (39), 143 (100, M—$COCH_3$), 142 (13), 141 (32), 129 (17), 128 (71), 127 (16), 115 (26), 43 (77, C^+OCH_3).

^{1}H NMR (80 MHz, $CDCl_3$): δ 2.41 (3H, s, ArC*H*$_3$ or COC*H*$_3$), 2.42 (3H, s, COC*H*$_3$ or ArC*H*$_3$),

$$\text{2.51 (3H, t, } {}^5J \text{ 2.39 Hz, } =C^1\text{—}CH_3\text{),}$$

3.61 (2H, q, ^5J 2.39 Hz, CH_2), 7.11—7.41 (3H, m, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 12.85 (OFR q), 21.39 (q), 30.02 (q), 38.80 (t), 122.02 (d), 123.62 (d), 129.01 (d), 136.36 (s), 137.82 (s), 140.24 (s), 145.60 (s), 149.87 (s), 196.49 (s).

e) 2-Bromo-1-(3,5-dimethyl-1H-inden-2-yl)ethanone

Bromine (2.80 g) is added to 1-(3,5-dimethyl-inden-2-yl)ethanone (3.00 g) in dry ether (30 ml), while keeping the temperature at +10°C. The mixture is extracted with water, several times with the diluted $NaHCO_3$ solution, again with water, dried and evaporated under reduced pressure to afford the product (2.54 g, 59%).

2-bromo-1-(3,5-dimethyl-1H-inden-2-yl)ethanone:

MS: 266 and 264 (13 and 13, $M^{+\cdot}$), 185 (4, M—Br), 171 (100, M—CH_2Br), 157 (13), 143 (49, M—$COCH_2Br$), 142 (18), 141 (32), 128 (27), 115 (18).

f) 4(5)-(3,5-Dimethyl-1H-inden-2-yl)imidazole

4(5)-(3,5-Dimethyl-1H-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(3,5-dimethyl-1H-inden-2-yl)ethanone (14.3 g) with formamide (130 ml) as described earlier in Example 4d. The crude base is purified by flash chromatography (solvent system: methylene chloride-methanol 9.5:0.5). The 4(5)-(3,5-dimethyl-1H-inden-2-yl)imidazole thus obtained is converted to its hydrochloride salt. The base is dissolved in ethyl acetate. After dry hydrogen chloride in ethyl acetate is added the hydrochloride salt precipitates.

The base of 4(5)-(3,5-dimethyl-1H-inden-2-yl)imidazole:

^{1}H NMR (80 MHz, MeOH-d_4):

$$\text{δ 2.28 (3H, t, } {}^5J \text{ 2.05 Hz, } =C^1\text{—}CH_3\text{),}$$

2.38 (3H, s, ArC*H*$_3$), 3.64 (2H, q, ^5J 2.05 Hz, CH_2), 6.91—7.33 (4H, m, aromatic and im-5(4)), 7.73 (1H, d, ^4J 0.86 Hz, im-2).

The hydrochloride salt of 4(5)-(1,6-dimethyl-inden-2-yl)imidazole:

^{1}H NMR (80 MHz, MeOH-d_4):

$$\text{δ 2.33 (3H, t, } {}^5J \text{ 2.22 Hz, } =C^1\text{—}CH_3\text{),}$$

2.41 (3H, s, ArC*H*$_3$), 3.71 (2H, q, ^5J 2.22 Hz, CH_2), 7.05—7.43 (3H, m, aromatic), 7.70 (1H, d, im-5(4)), 8.96 (1H, d, ^4J 1.37 Hz, im-2).

g) *cis*-4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole

The hydrochloride salt of 4(5)-(3,5-dimethyl-inden-2-yl)imidazole (0.55 g) is dissolved in water (6 ml)-ethanol (3 ml)-concentrated hydrochloric acid (4 ml) solution. Hydrogenation is performed as it is described in Example 4e. The *cis*-4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole is converted into the hydrochloride salt in ethylacetate. The melting point of the hydrochloride salt is 192—196°C.

The hydrochloride salt of *cis*-4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole:

MS: 212 (100, $M^{+\cdot}$), 211 (25, M—H), 197 (73, M—CH_3), 183 (41), 170 (14), 168 (14), 144 (25), 141 (10), 131 (22), 129 (19), 128 (20), 115 (14), 98 (12), 91 (15).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.93 (3H, d, J 7.01 Hz, >CHCH_3), 2.31 (3H, s, ArCH_3), 3.16—4.00 (4H, m, H^1, $H^{2'}$ and $H^{3'}_2$), 6.96—7.12 (3H, m, aromatic), 7.24 (1H, broad s, im-5(4)), 8.85 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): δ 16.49 (OFR q), 21.39 (q), 36.17 (t), 41.83 (d), 43.98 (d), 117.17 (d), 125.14 (d), 125.38 (d), 128.74 (d), 134.63 (d), 136.55 (s), 137.82 (s), 138.70 (s), 148.14 (s).

Example 6

cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole

Method A:

a) α-Acetyl-2-methylbenzenepropanoic acid ethyl ester

The starting material, α-acetyl-2-methylbenzenepropanoic acid ethyl ester can be prepared for example according to the publication by L. Borowiecki and A. Kazubski (*Pol. J. Chem. 52* (1978) 1447). Yield 64%, b.p. 142—152°C/1.5 mmHg (199.9 Pa).

α-acetyl-2-methylbenzenepropanoic acid ethyl ester:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.19 (3H, t, J 7.18 Hz, CH_2CH_3), 2.18 (3H, s, CH_3CO or ArCH_3), 2.32 (3H, s, ArCH_3 or CH_3CO), 3.17 (2H, distorted d, J_{ab} 7.58 Hz, >CHCH_2—), 3.76 (1H, distorted t, J_{ab} 7.58 Hz, >C*H*CH_2—), 4.14 (2H, q, J 7.18 Hz, CH_2CH_3), 7.10 (4H, s, aromatic).

b) 3,7-Dimethyl-indene-2-carboxylic acid

The 3,7-dimethyl-indene-2-carboxylic acid can be prepared by the treatment of α-acetyl-2-methylbenzenepropanoic acid ethyl ester with sulfuric acid (Shadbolt, R. S., *J. Chem. Soc.* (C), (1970) 920). Recrystallization from ethanol, m.p. 190—193°C. Yield 61%.

3,7-dimethyl-indene-2-carboxylic acid:

^{1}H NMR (80 MHz, DMSO-d_6): δ 2.33 (3H, s, ArCH_3),

2.46 (3H, t, ^{5}J 2.39 Hz $=C^1(CH_3)$—),

3.48 (2H, q, ^{5}J 2.39 Hz, CH_2), 7.09—7.42 (4H, m, aromatic and —COO*H*).

^{13}C NMR (20 MHz, DMSO-d_6): δ 12.04 (OFR, q), 17.86 (q), 37.44 (t), 118.51 (d), 126.68 (d), 128.26 (d), 130.11 (s), 132.71 (s), 141.67 (s), 144.42 (s), 149.81 (s), 166.43 (s).

c) 3,7-Dimethyl-indene-2-carboxylic acid chloride

3,7-Dimethyl-indene-2-carboxylic acid is converted to its acid chloride by treatment with thionyl chloride. Yield 100%.

d) 1-(3,7-Dimethyl-inden-2-yl)ethanone

1-(3,7-Dimethyl-inden-2-yl)ethanone is prepared by the same procedure as 1-(3,5-dimethyl-inden-2-yl)ethanone in Example 5d. Yield 75%.

1-(3,7-Dimethyl-inden-2-yl)ethanone:

MS: 186 (60, $M^{+\cdot}$), 171 (29, M—CH_3), 144 (33), 143 (100, M—$COCH_3$), 141 (27), 129 (18), 128 (66), 127 (15), 115 (28), 43 (60, $COCH_3$).

^{1}H NMR (80 MHz, $CDCl_3$): δ 2.38 (3H, s, ArCH_3 or COCH_3), 2.46 (3H, s, COCH_3 or ArCH_3),

2.53 (3H, t, ^{5}J 2.39 Hz, $=C^1(CH_3)$—),

3.55 (2H, q, ^{5}J 2.39 Hz, CH_2), 7.10—7.46 (3H, m, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 13.13 (OFR q), 18.33 (q), 30.14 (q), 38.13 (t), 119.23 (d), 127.13 (d), 129.10 (d), 133.25 (s), 137.55 (s), 141.84 (s), 145.14 (s), 150.17 (s), 196.46 (s).

e) 2-Bromo-1-(3,7-dimethyl-inden-2-yl)ethanone

2-Bromo-1-(3,7-dimethyl-inden-2-yl)ethanone is prepared by the same procedure as 2-bromo-1-(3,5-dimethyl-inden-2-yl)ethanone in Example 5e. Yield 45%.

2-bromo-1-(3,7-dimethyl-inden-2-yl)ethanone:

MS: 266 and 264 (14 and 15, $M^{+\cdot}$), 185 (3, M—Br), 171 (100, M—CH_2Br), 157 (13), 143 (M—$COCH_2$Br), 142 (18), 141 (33), 128 (32), 115 (21).

f) 4(5)-(3,7-Dimethyl-inden-2-yl)imidazole

4(5)-(3,7-Dimethyl-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(3,7-dimethyl-inden-2-yl)ethanone (8.7 g) with formamide (330 ml) as described earlier in Example 4d. The product as base is extracted into methylene chloride. The yield of the base product is 3.0 g, 44%.

g) *cis*-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole

The crude product of 4(5)-(3,7-dimethyl-inden-2-yl)imidazole (3.0 g) is dissolved in water (35 ml)-ethanol (18 ml)-concentrated hydrochloric acid (17.4 ml) solution. Then 0.30 g of 10% Pd/C is added and the mixture is stirred under a hydrogen atmosphere at about 60°C until no more hydrogen is consumed. Work-up of the reaction mixture is as before in Example 4e. The crude imidazole derivative is purified by flash chromatography (solvent system: methylene chloride/methanol 9.5/0.5). The *cis*-4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole is converted into its hydrochloride salt in isopropanol/ethyl acetate and ether is added to precipitate the salt, m.p. 135—140°C.

The hydrochloride salt of *cis*-4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole:

MS: 212 (100, $M^{+\cdot}$), 211 (30, M—CH_3), 197 (80), 184 (13), 183 (34), 182 (11), 170 (13), 168 (16), 144 (35), 143 (10), 141 (11), 131 (14), 129 (15), 128 (12), 127 (10), 115 (17), 98 (16), 91 (15).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.92 (3H, d, ^{3}J 6.84 Hz, CH_3CH<), 2.31 (3H, s, ArCH_3), 3.14—4.01 (4H, m, H^1, H^2 and $H_2{}^3$), 6.98—7.09 (3H, m, aromatic), 7.28 (1H, broad s, im-5(4)), 8.83 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): δ 16.79 (OFR q), 19.06 (q), 34.95 (t), 41.13 (d), 44.16 (d), 117.20 (d), 122.14 (d), 128.25 (d), 128.77 (d), 134.67 (d), 134.88 (s), 136.49 (s), 140.30 (s), 147.87 (s).

Method B:

a) *cis*-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid

3,7-Dimethyl-indene-2-carboxylic acid (35.5 g) is hydrogenated in ethanol-water (700 ml — 70 ml) over 10% palladium on carbon at ambient temperature. After filtration ethanol is evaporated. Water is added and the precipitated *cis*-2,3-dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid is filtrated. Yield 33.3 g, 93% M.p. 132—135°C.

cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid:

^{1}H NMR (80 MHz, DMSO-d_6): δ 1.08 (3H, d, J 6.78 Hz, CH_3CH<), 2.20 (3H, s, ArCH_3), 2.70—3.67 (4H, m, H^1, H^2 and $H_2{}^3$), 6.88—7.08 (3H, m, aromatic), 12.15 (1H, broad s, —COOH).

^{13}C NMR (20 MHz, DMSO-d_6): δ 16.95 (OFR q), 18.49 (q), 31.39 (t), 41.01 (d), 47.43 (d), 120.60 (d), 126.44 (d), 127.14 (d), 133.01 (s), 139.64 (s), 146.45 (s), 174.33 (s).

b) *cis*-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid chloride

cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid is converted to its acid chloride by treatment with thionyl chloride. Yield 92%.

cis-2,3-dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid chloride:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.44 (3H, d, J 6.67 Hz, CH_3CH<), 2.25 (3H, s, ArCH_3), 2.84—4.02 (4H, m, H^1, H^2, $H_2{}^3$), 6.92—7.11 (3H, m, aromatic).

c) *cis*-1-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone is prepared by the same procedure as 1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone in Example 4b. B.p. 181—182°C/1 mmHg. Yield 55%.

cis-1-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.37 (3H, d, ^{3}J 6.65 Hz, CH_3CH<), 2.26 (6H, 2s, COCH_3 and ArCH_3), 2.85—3.72 (4H, m, H^1, H^2 and $H_2{}^3$ of the indane ring), 6.88—7.16 (3H, m, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 18.82 (OFR q), 19.91 (q), 28.99 (q), 33.44 (t), 41.85 (d), 60.65 (d), 120.56 (d), 127.04 (d), 127.56 (d), 133.55 (s), 139.30 (s), 146.17 (s), 209.14 (s).

d) 2-Bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone

Bromination of *cis*-1-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone (11.78 g) is performed with bromine (10.00 g)/methylene chloride (40 ml) in methylene chloride (120 ml) as in the case of 1-(1,6-dimethyl-inden-2-yl)ethanone in Example 5e. Work-up of the reaction mixture gives the light yellow oil, which contains two isomers (a and b) of 2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone.

2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone:

MS of the isomer a: 348, 346, 344 (0.3, 0.9, 0.1, $M^{+\cdot}$), 267 and 265 (77 and 77, M—Br), 186 (10), 171 (18), 157 (18), 144 (64), 143 (74), 141 (23), 129 (74), 128 (100), 127 (29), 123 (16), 121 (16), 115 (24), 43 (13).

MS of the isomer b: 348, 346, 344 (all invisible, $M^{+\cdot}$), 267 and 265 (71 and 78, M—Br), 186 (18), 185 (16), 171 (38), 157 (24), 144 (52), 143 (91), 141 (32), 129 (73), 128 (100), 127 (30), 123 (12), 121 (13), 115 (36), 43 (15).

e) 4(5)-(3,7-Dimethyl-inden-2-yl)imidazole

4(5)-(3,7-Dimethyl-inden-2-yl)imidazole is prepared from 2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone and formamide as described for 2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone in Example 4d.

f) *cis*-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole

cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole is obtained in a similar manner as in method Ag.

Example 7

4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole

a) 2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid

2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid can be prepared for example by the procedure of Huebner, C. F., Donoghue, E. M., Strachan, P. L., Beak, P. and Wenkert, E. (*J. Org. Chem. 27* (1962) 4465) or by the reaction of lithium N-isopropylcyclohexylamide and methyl iodide (Rathke, M. V. and Lindert, A., *J. Am. Chem. Soc. 93* (1971) 2318) with 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (prepared by the methylation of 2,3-dihydro-1H-indene-2-carboxylic acid in the presence of sulphuric acid) followed by hydrolysis.

2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.40 (3H, s, CH_3), AB quartet: γA 2.84, γB 3.52, J_{AB}, 15.73 Hz (4H, 2 × CH_2), 7.17 (4H, s, aromatic), about 9.3 (1H, broad s, COOH).

^{13}C NMR (20 MHz, $CDCl_3$): δ 24.84 (OFR q, CH_3), 43.94 (2 t, C_1 and C_3), 49.48 (s, C_2), 124.62 (2 d, aromatic), 126.62 (2 d, aromatic), 141.06 (2 s, C_8 and C_9), 183.65 (s, CO).

2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid chloride

A stirred mixture of 2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid (6.70 g) and thionyl chloride (70 ml) is heated under reflux for 14 hr. The excess of thionyl chloride is removed and the acid chloride is distilled. Yield 5.35 g, 72%, bp. 93—98°C/3 mmHg.

2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid chloride:


^{1}H NMR (80 MHz, $CDCl_3$): δ 1.51 (3H, s, CH_3), AB quartet: γA 2.91, γB 3.60, J_{AB} 15.90 Hz (4H, 2 × CH_2), 7.19 (4H, s, aromatic).

c) 1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone is prepared from 2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid chloride in the same way as it is described in Example 4b. Yield 75%.

1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone:

^{1}H NMR (80 MHz, $CDCl_3$):



δ 1.32 (3H, s, —CCH_3),

2.20 (3H, s, $COCH_3$), AB quartet: γA 2.76, γB 3.39, J_{AB} 15.73 Hz (4H, 2 × CH_2), 7.17 (4H, s, aromatic).

d) 2-Bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone (3.69 g) in methylene chloride (40 ml) is stirred and cooled at 10°C during the dropwise addition of bromine (2.82 g)/methylene chloride (10 ml). Work-up of the resultant solution gives 2-bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone.

2-bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone:

MS: 254 and 252 (2 and 2, $M^{+\cdot}$), 239 and 237 (0.5 and 0.5, M—CH_3), 173 (100, M—Br), 159 (39, M—CH_2Br), 155 (13), 145 (30), 143 (10), 131 (97, M—$COCH_2$Br), 130 (30), 129 (40), 128 (34), 127 (19), 116 (29), 115 (69), 91 (50), 77 (12), 63 (10), 43 (22).

e) 4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone (2.04 g) with formamide (60 ml) as described in Example 6, method Af. Purification of the crude base *via* flash chromatography (methylene chloride/methanol 9.75/0.25) gave pure 4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole. M.p. of the base 167—170°C.

The base of 4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole:

MS: 198 (44, $M^{+\cdot}$), 197 (13, M—H), 183 (100, M—CH_3), 129 (14), 128 (18), 115 (22), 91 (28), 77 (11).

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.48 (3H, s, CH_3), AB quartet: δ_A 2.98, δ_B 3.32, J_{AB}, 15.39 Hz (4H, 2 × CH_2), 6.78 (1H, s, im-5(4)), 7.16 (4H, s, aromatic), 7.54 (1H, s, im-2), 8.74 (1H, s, >NH).

Example 8

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

a) 2-Bromo-1-(2-bromo-2,3-dihydro-1H-inden-2-yl)ethanone

The procedure of Example 1 a) is repeated, except that the amount of bromide is doubled. After removal of the solvent the crude product is used as such in step b).

b) 4(5)-(1H-Inden-2-yl)imidazole

The procedure of Example 1 b) is repeated. The product is recrystallized from methylene chloride.

c) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidzole

The procedure of Example 2c is repeated except that 4(5)-(1H-inden-2-yl)imidazole is used in place of 4(5)-(2,3-dihydrobenzofuran-2-yl)imidazole. When the uptake of hydrogen ceases, the reaction mixture is filtered and the filtrate is made alkaline with sodium hydroxide. The separated oil is extracted into methylene chloride. The combined extracts are washed with water, dried over Na_2SO_4, and evaporated to dryness. The crude product is purified by converting it into the hydrochloride in ethyl acteate. M.p.: 184—191°C.

Example 9

4(5)-(2,3-Dihydro-5-methyl-1H-inden-2-yl)imidazole

The procedure of Example is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 2-(2,3-dihydro-5-methyl-1H-inden-2-yl)ethanone. M.p. (HCl): 171—175°C.

^{1}H NMR (80 MHz, $CDCl_3$, as base): 2.3 (s, 3H), 2.8—3.8 (m, 5H), 6.8 (s, 1H), 7.0—7.1 (m, 3H), 7.5 (s, 1H), 9.9 (s, 1H).

Example 10

4(5)-(2,3-Dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole

The procedure of Example 1 is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 1-(2,3-dihydro-2-ethyl-5-methyl-1H-inden-2-yl)ethanone. M.p. 54—57°C as base.

MS: 226 (40%), 211 (12%), 197 (100%), 182 (7%), 128 (12%), 98 (17%), 84 (15%).

Example 11

4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)imidazole

The compound is prepared according to the procedure of example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and ethyl bromide as starting materials. M.p. (HCl): 211—215°C.

^{1}H NMR (80 MHz, $CDCl_3$, as base): 0.78 (t, 3H), 1.88 (q, 2H), 3.17 (q, 4H), 6.75 (s, 1H), 7.13 (s, 4H), 7.53 (s, 1H), 10.01 (s, 1H).

Example 12

4(5)-(2,3-Dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole

The procedure of Example 1 is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 1-(2,3-dihydro-2,5-dimethyl-1H-inden-2-yl)ethanone. M.p.: 148—151°C as base.

^{1}H NMR (80 MHz, $CDCl_3$, as hydrochloride): 1.51 (s, 3H), 2.27 (s, 3H), AB quartet δ_A 3.04, δ_B 3.24 J_{AB} 15.45 Hz (4H, 2 × CH_2), 6.87—6.99 (m, 4H), 9.04 (s, 1H), 14 (broad band, 2H).

Example 13

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

a) 2,3-Dihydro-1H-inden-2-yl glyoxal diethyl acetal

0.73 g of magnesium turnings are covered with 90 ml of dry diethylether. To that mixutre is then added 6 g of 2-bromoindane in 20 ml of dry diethylether at such a rate that a gentle boiling is maintained. When the magnesium turnings have reacted the solution containing the Grignard reagent is cooled to room temperature. The reaction mixture is then added dropwise, over a period of 3 hours, to a cooled (0—5°C) solution of diethoxyacetic acid piperidinyl amide (6.5 g) in 20 ml of dry diethylether. After the addition is complete, the reaction mixture is stirred for two hours at about 5°C. The mixture is then poured into a cold 2% sulfuric acid solution (50 ml). The solution is extracted with ether and the combined ether extracts are washed with water and evaporated to dryness to give a residue of crude product, which is used without purification in step b).

b) 1,1-Diethoxy-2-hydroxy-2-(2,3-dihydro-1H-inden-2-yl)ethane

4 g of crude 2,3-dihydro-1H-inden-2-yl glyoxal diethyl acetal is dissolved in 20 ml of ethanol and 3.8 g of sodium borohydride is added in small portions at a temperature below 30°C. After the addition is complete, the mixture is stirred overnight at room temperature. About 15 ml of ethanol is distilled off and 30 ml of water is added. The solution is extracted with methylene chloride. The combined methyl chloride extracts are washed with water, dried with sodium sulfate, and evaporated to dryness. The yield is about 4 g of oil, which is used directly in step c).

c) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

4 g of the oil from the preceding step and 15 ml of formamide are combined and stirred at 150°C while passing ammonia gas into the solution for 6 hours. The mixture is cooled to room temperature and 40 ml of water is added. Concentrated hydrochloric acid is added with cooling until the pH is 3—4.

The solution is washed with toluene, cooled and the pH is adjusted to 10—12 with 20% sodium hydroxide solution. The mixture is extracted with methylene chloride and the combined methylene chloride extracts are extracted with 10% acetic acid solution. The combined acetic acid extracts are made alkaline (pH 10—12) with 20% sodium hydroxide solution. The product is extracted into chloroform, and the combined chloroform extracts washed with water and dried with sodium sulfate. The solution is evaporated to dryness to give the product as base.

The hydrochloride is prepared by dissolving the base in ethyl acetate and adding HCl-ethyl acetate until pH is about 4. The mixture is cooled and filtered and the filter cake washed with a small amont of ethyl acetate. M.p. 185—193°C.

Example 14

4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole

The starting material, 1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone can be prepared from 1,2,3,4-tetrahydro-2-naphthoic acid chloride for example by the procedure of Newman, M.S. and Mangham, J.R. (*J. Am. Chem. Soc. 71* (1949) 3342) or as described in this patent for many acid chlorides to afford the acetyl derivatives.

a) The mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone

Bromination of 1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone (3.00 g) in methylene chloride with bromine (2.75 g)/methylene chloride (10 ml) by the normal procedure described for example in Example 5 affords the mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone.

2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone:

MS: 254 and 252 (14 and 14, $M^{+\cdot}$), 173 (54, M—Br), 159 (21, M—CH_2Br), 150 (11), 145 (25), 131 (46, M—$COCH_2Br$), 130 (23), 129 (100), 128 (27), 127 (12), 116 (12), 115 (26), 91 (16).

2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone:

MS: 334, 332 and 330 (invisble, $M^{+\cdot}$), 253 and 251 (96 and 100, M—Br), 172 (32, M—Br—Br), 157 (11), 153 (14), 130 (25, M—Br—$COCH_2Br$), 129 (81), 128 (56), 127 (22), 115 (20).

b) 4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole

The mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone is heated with formamide as in the case of Example 4d to afford a mixture of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole and probably both 4(5)-(1,4-dihydronaphth-2-yl)imidazole and 4(5)-(3,4-dihydronaphth-2-yl)imidazole. This mixture is directly hydrated at about 70°C as in Example 4e to provide crude 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole. The product as base is purified by flash chromatography (solvent system: methylene chloride/methanol 9.5/0.5). M.p. of the hydrochloride salt of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole 168—177°C.

The hydrochloride salt of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole:

MS: 198 (100, $M^{+\cdot}$), 107 (64), 183 (31), 170 (22), 169 (30), 130 (22), 129 (18), 128 (23), 117 (16), 116 (10), 115 (30), 104 (77), 103 (23), 8 (12), 94 (12), 91 (16), 82 (30), 81 (15).

^{1}H NMR (80 MHz, MeOH-d_4): δ 1.66—2.46 (2H, m, —CH_2CH_2CH), 2.86—3.13 (5H, m, 2 × ArCH_2 and —$CH_2CH$$CH_2$), 7.11 (4H, s, aromatic), 7.34 (1H, m, im-5(4)), 8.85 (1H, d, ^{4}J 1.54 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): δ 29.23 (OFR t), 29.63 (t), 32.53 (d), 35.50 (t), 115.84 (d), 126.89 (d), 127.19 (d), 129.92 (2d) 134.70 (d), 135.43 (s), 136.52 (s), 139.45 (s).

Example 15

4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole

a) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester

1,2,3,4-Tetrahydro-2-naphthoic acid methyl ester (prepared by the methylation of 1,2,3,4-tetrahydro-2-naphthoic acid) is converted to 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester by the procedure of Rathke, M.V. and Lindert, A. (*J. Am. Chem. Soc. 93* (1971) 2318). B.p. 90—95°C/0.3 mmHg. Yield 88%.

1,2,3,4-Tetrahydro-2-naphthoic acid methyl ester:

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.88 (3H, t, J 7.69 Hz, —CH_2CH_3), 1.53—3.34 (8H, m, —CH_2CH_3 and the methylene protons of the ring), 3.64 (3H, s, $COOCH_3$), 7.07 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 8.77 (OFR q), 26.26 (t), 30.23 (t), 31.05 (t), 36.83 (t), 46.09 (s), 51.51 (q), 125.62 (2d), 128.52 (d), 129.07 (d), 134.91 (s), 135.37 (s), 176,66 (s).

b) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid

The mixture of 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester (32.3 g), sodium hydroxide (32.3 g), ethanol (450 ml) and water (323 ml) is refluxed for 8 hr. Ethanol is largely distilled in vacuo, the residue diluted with water and washed with ether. The aqueous solution gives an acidification with hydrochloric acid the desired 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid. The product is filter. Yield 22.2 g, 73%.

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid:

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.83 (3H, t, J 7.69 Hz, —CH_2CH_3), 1.55—3.33 (8H, m, —CH_2CH_3 and the methylene protons of the ring), 7.07 (3H, s, aromatic), 11.45 (1H, broad s, —COOH).

^{13}C NMR (20 MHz, $CDCl_3$): δ 8.75 (OFR q), 26.19 (t), 29.94 (t), 30.91 (t), 36.54 (t), 45.89 (s), 125.75 (2d), 128.63 (d), 129.14 (d), 134.68 (s), 135.35 (s), 183.06 (s).

c) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride

A mixture of 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid (22.0 g) and thionyl choride is boiled for 5 days. The acid chloride is distilled., B.p. 110—115°C/0.2 mmHg. Yield 21.6 g, 90%.

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride:

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.97 :3H, t, J 7.69 Hz, —CH_2CH_3), 1.67—3.38 (8H, m, —CH_2CH_3 and the methylene protons of the ring), 7.10 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 8.36 (OFR q), 26.00 (t), 30.70 (t), 30.79 (t), 37.11 (t), 56.57 (s), 126.05 (d), 126.24 (d), 128.66 (d), 129.08 (d), 133.38 (s), 134.65 (s), 178.46 (s).

d) 1-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride is converted to 1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone by the procedure described for example in Example 4b.

e) 2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone

Bromination of 1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone by the procedure of Example 7d yields 2-bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone.

2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone:

MS: 282 and 280 (4 and 4, $M^{+\cdot}$), 253 and 251 (8 and 8, M—CH_2CH_3), 201 (20, M—Br), 187 (28, M—CH_2Br), 159 (22, M—$COCH_2Br$), 157 (12), 145 (30), 131 (10), 130 (12), 129 (50), 128 (32), 127 (14), 117 (100), 115 (30), 91 (21), 77 (10), 43 (24).

f) 4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole

2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone is converted to 4(5)-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole by the procedure of Example 7e. M.p. of the hydrochloride salt 148—156°C.

The hydrochloride salt of 4(5)-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole;

MS: 226 (63, $M^{+\cdot}$), 211 (17, M—CH_3), 198 (25), 197 (100, M—CH_2CH_3), 195 (17), 129 (15), 128 (12), 115 (13), 104 (20), 98 (14), 82 (19), 81 (30), 69 (11).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.79 (3H, t, J 7.52 Hz, —CH_2CH_3), 1.63—3.34 (8H, m, —CH_2CH_3 and the methylene protons of the ring). 7.02—7.14 (5H, m, aromatic and im-4), 8.74 (1H, d, ^{4}J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d_4): δ 8.48 (OFR q), 27.70 (t), 33.30 (t), 34.00 (t), 38.54 (s), 39.48 (t), 117.91 (d), 126.99 (d), 127.11 (d), 129.66 (d), 130.14 (d), 135.02 (s), 135.20 (d), 136.20 (s), 140.40 (s).

Example 16

4(5)-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole

a) *cis*-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester is prepared from *cis*-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid (see Example 4) by the standard methods using methanol and concentrated sulphuric acid. Yield 91%.

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester:

^{1}H NMR (80 MHz, $CDCl_3$): δ 1.14 (3H, d, J 6.84 Hz, $CHCH_3$), 2.76—3.66 (4H, m, H^1, H^2 and H_2^3 of the indane ring), 3.72 (3H, s, —$COOCH_3$), 7.17 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 17.01 (OFR q), 33.21 (t), 41.93 (d), 48.53 (d), 51.37 (q), 123.481 (d), 124.45 (d), 126.66 (d), 126.81 (d), 140.92 (s), 146.76 (s), 173.98 (s).

b) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester is prepared by the procedure of Bathke, M.V. and Lindert, A. (*J. Am. Chem. Soc. 93* (1971) 2318). B.p. 90—95°C/0.3 mmHg. Yield 51%. The

product is probably the mixture of two isomers (*cis* the major isomer, *trans* the minor isomer).

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester (the *cis*-isomer):

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.86 (3H, t, J 7.18 Hz —CH_2CH_3), 1.122 (3H, d, J 7.18 Hz, >$CHCH_3$), 1.25—2.18 (2H, m, —CH_2CH_3), 3.10 (1H, q, J 7.18 Hz, >$CHCH_3$), AB quartet: D_A 2.82, D_B 3.52, J_{AB} 16.41 Hz (2H, H_2^3 of the indane ring), 3.70 (3H, s, $COOCH_3$), 7.15 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 9.84 (OFR q), 17.53 (q), 30.76 (t), 36.99 (t), 49.77 (d), 51.28 (q), 59.27 (s), 123.60 (d), 124.60 (d), 126.45 (d), 126.63 (d), 140.74 (s), 146.52 (s), 175.52 (s).

c) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid is synthesized by the method of Example 15b. Yield 97%.

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid (the *cis*-isomer):

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.93 (3H, t, J 7.18 Hz —CH_2CH_3), 1.23 (3H, d, J 7.18 Hz, >$CHCH_3$), 1.32—2.23 (2H, m, —CH_2CH_3), 3.13 (1H, q, J 7.18 Hz, >$CHCH_3$), AB quartet: D_A 2.83, D_B 3.49, J_{AB} 16.21 Hz (2H, H_2^3 of the indane ring), 7.15 (4H, s, aromatic), 10.70 (1H, broad s, —COOH).

^{13}C NMR (20 MHz, $CDCl_3$): δ 9.81 (OFR q), 17.26 (q), 30.64 (t), 36.90 (t), 49.59 (d), 59.12 (s), 123.57 (d), 124.57 (d), 126.54 (d), 126.72 (d), 140.59 (s), 146.25 (s), 181.79 (s).

d) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride is prepared by the standard method using thionyl chloride and has the boiling point 105°C/0.3 mmHg. Yield 94%.

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride (the *cis*-isomer):

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.95 (3H, t, J 7.18 Hz —CH_2CH_3), 1.28 (3H, d, J 7.01 Hz, >$CHCH_3$), 1.40—2.31 (2H, m, —CH_2CH_3), 3.18 (1H, q, J 7.01 Hz, >$CHCH_3$), AB quartet: D_A 2.92, D_B 3.50, J_{AB} 16.24Hz (2H, H_2^3 of the indane ring), 7.17 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 9.38 (OFR q), 17.86 (q), 30.88 (t), 36.60 (t), 49.74 (d), 68.75 (s), 123.75 (d), 124.87 (d), 127.02 (2d), 139.07 (s), 145.61 (s), 177.21 (s).

e) 1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone is synthesized by the method of Example 4b. Yield 69%.

1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone (the *cis*-isomer):

^{1}H NMR (80 MHz, $CDCl_3$): δ 0.81 (3H, t, J 7.18 Hz —CH_2CH_3), 1.06 (3H, d, J 7.18 Hz, >$CHCH_3$), about 1.2—2.2 (2H, m, —CH_2CH_3), 2.10 (3H, s, $COCH_3$), 3.10 (1H, q, J 7.18 Hz, >$CHCH_3$), AB quartet: D_A 2.75, D_B 3.45, J_{AB} 16.41 Hz (2H, H_2^3 of the indane ring), 7.15 (4H, s, aromatic).

^{13}C NMR (20 MHz, $CDCl_3$): δ 9.60 (OFR q), 17.35 (q), 27.55 (q), 29.82 (t), 35.33 (t), 49.04 (d), 64.93 (s), 123.60 (d), 124.87 (d), 126.60 (d), 126.75 (d), 140.80 (s), 146.67 (s), 210.85 (s).

f) 2-Bromo-1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone

2-Bromo-1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone is prepared from 1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone (21.6 g) by treatment with bromine (17.6 g) in methylene chloride (300 ml). Yield 65%.

g) 4(5)-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole

The procedure of Example 1b is used to synthesise 4(5)-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole. Yield 28%. The base obtained is converted to its hydrochloride salt in dry ether. The hydrochloride salt is recrystallized from ethyl acetate — petroleum ether. The product is the mixture of two isomers, *cis* 85% and *trans* 15%. The melting point of the hydrochloride salt is 154—158°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole (the mixture of the *cis*- and *trans*-isomer, 85% and 15%):

MS: 226 (30, $M^{+\cdot}$), 211 (15, M—CH_3), 197 (100 M—CH_2CH_3), 182 (10), 129 (10), 128 (10), 115 (10), 91 (12).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.79 (3H, distorted t, ^{3}J 7.35 Hz —CH_2CH_3), 0.95 (3H, d, ^{3}J 7.18 Hz, >$CHCH_3$, the *cis*-isomer), 1.28 (d, J 7.18 Hz, >$CHCH_3$, the *trans*-isomer), 1.47—2.27 (2H, m, —CH_2CH_3), 2.99—3.48 (3H, m, H^1 and H_2^3 protons of the indane ring), 7.14—7.31 (5H, m, aromatic and im-4(5)), 8.90 (1H, d, ^{4}J 1.54 Hz, im-5).

The *cis*-isomer ^{13}C NMR (MeOH-d_4): δ 9.72 (OFR q), 16.47 (q), 31.91 (t), 40.69 (t), 51.31 (d), 52.49 (s), 118.24 (d), 124.75 (d), 125.48 (d), 128.02 (2d), 135.08 (d), 138.83 (s), 141.10 (s), 147.70 (s).

Example 17

4(5)-(2,3-Dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and *n*-propyl bromide as starting materials. M.p. of the hydrochloric salt: 169°—171°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole:

MS: 226 (25, $M^{+\cdot}$), 197 (17, M—CH_2CH_3), 183 (100, M—$CH_2CH_2CH_3$), 115 (13), 91 (17).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.79—1.31 (5H, m, 0.88 distorted t, CH_2CH_3), 1.79—1.99 (2H, m, $CH_2CH_2CH_3$), AB quartet: $D_A = D_B$ 3.23, J_{AB} 16.4 Hz (4H, H_2^1 and H_2^3 of the indane ring), 7.05—7.25 (4H, m, aromatic), 7.31 (1H, d, ^{4}J 1.4Hz, im-5(4)), 8.82 (1H, d, im-2, ^{4}J 1.4 Hz).

Example 18

4(5)-(2,3-Dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and *n*-butyl bromide as starting materials. M.p. of the hydrochloride salt: 129—132°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole:

MS: 240 (22, $M^{+\cdot}$), 197 (12, M—$CH_2CH_2CH_3$), 183 (100, M—$CH_2CH_2CH_2CH_3$), 170 (24), 141 (23), 129 (10), 115 (15), 97 (11), 91 (17), 81 (16), 77 (38), 69 (16), 57 (18), 55 (17), 51 (10).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.86 (3H, distorted t, CH_3), 1.00—1.50 (4H, m, $CH_2CH_2CH_3$), 1.81—2.00 (2H, m, $CH_2CH_2CH_2CH_3$), AB quartet: $D_A = D_B$ 3.23, J_{AB} 16.4 Hz (4H, H_2^1 and H_2^3 protons of the indane ring), 7.05—7.25 (4H, m, aromatic), 7.31 (1H, d, ^{4}J 1.4 Hz, im-5(4)), 8.81 (1H, d, ^{4}J 1.4 Hz, im-2).

Example 19

4(5)-(2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

a) 4(5)-(2,3-Dihydro-2-ethyl-1-oxo-1H-inden-2-yl)imidazole

2-Acetyl-1-indanone (Liebigs Ann. Chem. 347 (1906) 112) is alkylated with ethylbromide in acetone in the presence of sodiumcarbonate to 2-acetyl-2-ethyl-1-indanone. The acetyl group is brominated with bromine in methanol and to imidazole by heating in formamide as before. The melting point of the product as base is 126—127°C (from ethyl acetate).

b) 4(5)-2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

The carbonyl group of oxo inden imidazole from the step a) is reduced to the alcohol group with sodium borohydride in ethanol. The product is the mixture of cis-trans stereoisomers, the purification of which is accomplished by liquid chromatography.

cis-isomer as hydrochloride (m.p. 184—185°C):

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.73 (3H, t), 1.86 (2H, m), 3.36 (2H, m), 3.61 (3H, s), 5.15 (1H, s), 7.06 (1H, d), 7.2—7.4 (4H, m), 8.69 (1H, d).

trans-isomer as hydrochloride:

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.80 (3H, t), 1.84 (2H, m), 3.15 (2H, m), 3.24 (3H, s), 5.15 (1H, s), 6.87 (1H, d), 7.2—7.4 (4H, m), 8.54 (1H, d).


Example 20

4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)-imidazole

The oxo derivative prepared in the example 19 (step a) or the hydroxy derivative (step b) is hydrogenated in 2 N hydrochloric acid in the presence of 10% palladium on carbon at 70°C. When the uptake of hydrogen ceases, the reaction mixture is filtered and made alkaline. The product is extracted with methylene chloride which is washed with water, dried and evaporated to dryness. From the residue, which is the product as base, is made the hydrochloride using dry hydrogen chloride in ethyl acetate. It has M.p.: 211—215°C.

Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE

1. Substituted imidazoles of the formula



(I)

Example 17

4(5)-(2,3-Dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and *n*-propyl bromide as starting materials. M.p. of the hydrochloric salt: 169°—171°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-*n*-propyl-1H-inden-2-yl)imidazole:

MS: 226 (25, $M^{+\cdot}$), 197 (17, M—CH_2CH_3), 183 (100, M—$CH_2CH_2CH_3$), 115 (13), 91 (17).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.79—1.31 (5H, m, 0.88 distorted t, CH_2CH_3), 1.79—1.99 (2H, m, $CH_2CH_2CH_3$), AB quartet: $D_A = D_B$ 3.23, J_{AB} 16.4 Hz (4H, H_2^1 and H_2^3 of the indane ring), 7.05—7.25 (4H, m, aromatic), 7.31 (1H, d, ^{4}J 1.4Hz, im-5(4)), 8.82 (1H, d, im-2, ^{4}J 1.4 Hz).

Example 18

4(5)-(2,3-Dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and *n*-butyl bromide as starting materials. M.p. of the hydrochloride salt: 129—132°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-*n*-butyl-1H-inden-2-yl)imidazole:

MS: 240 (22, $M^{+\cdot}$), 197 (12, M—$CH_2CH_2CH_3$), 183 (100, M—$CH_2CH_2CH_2CH_3$), 170 (24), 141 (23), 129 (10), 115 (15), 97 (11), 91 (17), 81 (16), 77 (38), 69 (16), 57 (18), 55 (17), 51 (10).

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.86 (3H, distorted t, CH_3), 1.00—1.50 (4H, m, $CH_2CH_2CH_3$), 1.81—2.00 (2H, m, $CH_2CH_2CH_2CH_3$), AB quartet: $D_A = D_B$ 3.23, J_{AB} 16.4 Hz (4H, H_2^1 and H_2^3 protons of the indane ring), 7.05—7.25 (4H, m, aromatic), 7.31 (1H, d, ^{4}J 1.4 Hz, im-5(4)), 8.81 (1H, d, ^{4}J 1.4 Hz, im-2).

Example 19

4(5)-(2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

a) 4(5)-(2,3-Dihydro-2-ethyl-1-oxo-1H-inden-2-yl)imidazole

2-Acetyl-1-indanone (Liebigs Ann. Chem. 347 (1906) 112) is alkylated with ethylbromide in acetone in the presence of sodiumcarbonate to 2-acetyl-2-ethyl-1-indanone. The acetyl group is brominated with bromine in methanol and to imidazole by heating in formamide as before. The melting point of the product as base is 126—127°C (from ethyl acetate).

b) 4(5)-2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

The carbonyl group of oxo inden imidazole from the step a) is reduced to the alcohol group with sodium borohydride in ethanol. The product is the mixture of cis-trans stereoisomers, the purification of which is accomplished by liquid chromatography.

cis-isomer as hydrochloride (m.p. 184—185°C):

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.73 (3H, t), 1.86 (2H, m), 3.36 (2H, m), 3.61 (3H, s), 5.15 (1H, s), 7.06 (1H, d), 7.2—7.4 (4H, m), 8.69 (1H, d).

trans-isomer as hydrochloride:

^{1}H NMR (80 MHz, MeOH-d_4): δ 0.80 (3H, t), 1.84 (2H, m), 3.15 (2H, m), 3.24 (3H, s), 5.15 (1H, s), 6.87 (1H, d), 7.2—7.4 (4H, m), 8.54 (1H, d).


Example 20

4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)-imidazole

The oxo derivative prepared in the example 19 (step a) or the hydroxy derivative (step b) is hydrogenated in 2 N hydrochloric acid in the presence of 10% palladium on carbon at 70°C. When the uptake of hydrogen ceases, the reaction mixture is filtered and made alkaline. The product is extracted with methylene chloride which is washed with water, dried and evaporated to dryness. From the residue, which is the product as base, is made the hydrochloride using dry hydrogen chloride in ethyl acetate. It has M.p.: 211—215°C.

Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE

1. Substituted imidazoles of the formula



(I)

and their non-toxic acid addition salts, wherein X is —CH_2—, —CH_2CH_2— or —O—, R_1 is H, alkyl of 1 to 4 carbon atoms, alkenyl of 2 to 4 carbon atoms, OCH_3, or OCH_2CH_3; R_2 is H, CH_3, CH_2CH_3, OCH_3 or OH, R_3 is H, CH_3, CH_2CH_3, OCH_3 or Hal and R_4 is H, CH_3, CH_2CH_3, OCH_3 or Hal, and Hal is halogen.

2. Substituted imidazoles according to claim 1 wherein X is —CH_2—.

3. Substituted imidazoles according to claim 1 wherein X is —CH_2CH_2—.

4. Substituted imidazoles according to claim 1 wherein X is —O—.

5. Substituted imidazoles according to claim 1 wherein R_1 is hydrogen, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3.

6. Substituted imidazoles according to claim 1 wherein R_1 is hydrogen, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 and X is CH_2.

7. Substituted imidazoles according to claim 1 wherein R_1 is hydrogen, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 and X is CH_2 and R_2, R_3 and R_4 are hydrogen.

8. 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole.

9. 4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole.

10. 4(5)-(5-Bromo-2,3-dihydrobenzofuran-2-yl)imidazole.

11. 4(5)-(2,3-Dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole.

12. 4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole.

13. 4(5)-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole.

14. 4(5)-(2,3-Dihydro-2-n-propyl-1H-inden-2-yl)imidazole.

15. 4(5)-(2,3-Dihydro-4-methyl-1H-inden-2-yl)imidazole.

16. 4(5)-(2,3-Dihydro-5-methyl-1H-inden-2-yl)imidazole.

17. 4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole.

18. 4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole.

19. 4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole.

20. 4(5)-(5-Chloro-2,3-dihydro-1H-inden-2-yl)imidazole.

21. 4(5)-(5-Bromo-2,3-dihydro-1H-inden-2-yl)imidazole.

22. 4(5)-(2,3-Dihydro-1-hydroxy-1H-inden-2-yl)imidazole.

23. 4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole.

24. 4(5)-(4-Chloro-2,3-dihydro-1H-inden-2-yl)imidazole.

25. 4(5)-(4-Bromo 2,3-dihydro-1H-inden-2-yl)imidazole.

26. 4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)imidazole.

27. 4(5)-(2,3-Dihydro-2-n-butyl-1H-inden-2-yl)imidazole.


28. 4(5)-(2,3-Dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole.

29. 4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole.


30. 4(5)-(2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole.

31. Process for the preparation of an imidazole as claimed in claim 1, wherien R_1 is hydrogen and R_3 and R_4 are as defined in claim 1 and R_2 is hydrogen, methyl or ethyl, which comprises:

a) halogenating a compound of formula




wherein, R_2, R_3 and R_4 are as defined in claim 1 to give a product of the formula




wherein Hal is Cl or Br

b) reacting the said product with formamide to give a compound of formula




c) which is then hydrogenated catalytically to give a compound as claimed in claim 1.

32. A process for the preparation of a compound as claimed in claim 1, which comprises reacting a compound of formula




wherein R_5, R_6, R_7 and R_8 are each hydrogen, hydroxy, halogen, amino, -O-alkyl containing 1 to 7 carbon atoms, or




(wherein R_9 is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms); and wherein R_5 and R_7 can be combined to form a keto group, or R_6 and R_8 can be combined to form a keto group, with formamide to give a compound of formula (I) as defined in claim 1.

33. A process for the preparation of a compound as claimed in claim 1 wherein R_3 is a halogen and R_4 is H or both R_3 and R_4 are halogen atoms, which comprises: halogenating a compound of formula




to give a compound as defined in claim 1.


34. A process for the preparation of a compound as claimed in claim 1 wherein R_1 is hydrogen, R_3, R_4 and X are as defined in claim 1 and R_2 is hydrogen, methyl or ethyl, which comprises brominating a compound of formula



to give a compound of formula




which is reacted with formamide to produce a compound of formula




which is hydrogenated to give a compound of formula (I).


35. A process for the preparation of a compound as claimed in claim 1, which comprises reacting a compound of the formula




wherein R is a benzyl group with thionyl chloride to give a compound of formula:




which is reacted with sodium cyanide to give a compound of formula:



which is hydrolysed in alkaline solution to give a compound of formula:




which is reacted with polyphosphoric acid to give a compound of formula:




which is either

(a) hydrogenated in the presence of palladium on carbon as catalyst to give a compound of formula:




which is reduced with $NaBH_4$ to give a compound of the formula:




or

(b) reduced with $NaBH_4$ to give a compound of formula:



which is hydrogenated in the presence of palladium on carbon to give a compound of formula:




36. A pharmaceutical composition comprising a substituted imidazole as claimed in any one of claims 1 to 30 in association with a compatible, pharmaceutically acceptable carrier.

37. An imidazole derivative as claimed in any one of claims 1 to 30 or a non-toxic acid addition salt for use in therapy as an α_2-receptor antagonist.


Claims for the Contracting State: AT

1. A process for the preparation of a substituted imidazole of the formula




(I)


and its non-toxic acid addition salts, wherein X is $—CH_2—$, $—CH_2CH_2—$ or —O—, R_1 is H, alkyl of 1—4 carbon atoms, alkenyl of 2 to 4 carbon atoms, OCH_3 or OCH_2CH_3, R_2 is H, CH_3, CH_2CH_3, OCH_3 or OH, R_3 is H, CH_3, CH_2CH_3, OCH_3 or Hal, R_4 is H, CH_3, CH_2CH_3, OCH_3 or Hal, and Hal is halogen which comprises halogenating a compound of formula



wherein R_2, R_3 and R_4 are as defined above, to give a product of formula




wherein Hal is Cl or Br, reacting the said product with formamide to give a compound of formula




and hydrogenating the later catalytically to give a compound of formula (1), wherein R_1 is hydrogen, R_3 and R_4 are as defined above, and R_2 is hydrogen, methyl or ethyl.

2. A process for the preparation of a compound of formula I as defined in claim 1 which comprises reacting a compound of formula




wherein R_5, R_6, R_7 and R_8 are each hydrogen, hydroxy, halogen, amino, -O-alkyl containing 1 to 7 carbon aroms, or




(wherein R_9 is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atom); and wherein R_5 and R_7 can be combined to form a keto group, or R_6 and R_8 can be combined to form a keto group, with formamide to give a compound of formula (I) as defined in claim 1.

3. A process for the preparation of a compound of formula I as defined in claim 1 wherein R_3 is a halogen and R_4 is H or both R_3 and R_4 are halogen atoms which comprises halogenating a compound of formula




to give a compound of formula I as defined above.


4. A process for the preparation of a compound of formula I as defined in claim 1 wherein R_1 is hydrogen, R_3, R_4 and X are as defined above and R_2 is hydrogen, methyl or ethyl, which comprises brominating a compound of formula



to give a compound of the formula




which is reacted with formamide to produce a compound of formula




which is hydrogenated to give a compound as defined above.


5. A process for the preparation of a compound of formula I as defined in claim 1 which comprises reacting a compound of formula




wherein R is a benzyl group, with thionyl chloride to give a compound of formula:




which is reacted with sodium cyanide to give a compound of formula:



which is hydrolysed in alkaline solution to give a compound of formula:




which is reacted with polyphosphoric acid to give a compound of formula:




which is either

(a) hydrogenated in the presence of palladium on carbon as catalyst to give a compound of formula:




which is reduced with $NaBH_4$ to give a compound of formula:




or


(b) reduced with $NaBH_4$ to give a compound of formula:



which is hydrogenated in the presence of palladium on carbon to give a compound of formula:




6. A process for the preparation of a compound of formula I as defined in claim 1 which comprises halogenating and reacting with formamide a compound of the formula




* C L M S *

to give a compound of the formula




which is either

(a) hydrogenated in the presence of palladium on carbon to give a compound of formula




or


(b) reacted with $NaBH_4$ to give a product of formula




and then hydrogenated in the presence of palladium on carbon to give a compound of the formula




7. A process for the preparation of a compound of formula I as defined in claim 1 which comprises halogenating and reacting with formamide a compound of the formula



to give a compound of the formula




which is hydrogenated with Pd/C to give a compound of formula



8. A process as claimed in any one of claims 1 to 7 in which the product obtained is converted into a non-toxic acid addition salt.

Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LI LU NL SE

1. Substituierte Imidazole der allgemeinen Formel:



(I)

und deren nicht-toxische saure Additionssalze, wobei X —CH_2—, —CH_2CH_2— oder —O— ist, R_1 Wasserstoff, ein Alkyl mit 1 bis 4 Kohlenstoffatomen, ein Alkenyl mit 2 bis 4 Kohlenstoffatomen, OCH_3 oder OCH_2CH_3 ist, R_2 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder OH ist, R_3 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder Hal ist, R_4 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder Hal ist, und Hal für ein Halogen steht.

2. Substituierte Imidazole nach Anspruch 1, bei welchen X für —CH_2— steht.

3. Substituierte Imidazole nach Anspruch 1, bei welchen X für —CH_2CH_2— steht.

4. Substituierte Imidazole nach Anspruch 1, bei welchen X für —O— steht.

5. Substituierte Imidazole nach Anspruch 1, bei welchen R_1 Wasserstoff, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 ist.

6. Substituierte Imidazole nach Anspruch 1, bei welchen R_1 Wasserstoff, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 und X CH_2 ist.

7. Substituierte Imidazole nach Anspruch 1, bei welchen R_1 Wasserstoff, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 und X CH_2 ist, während R_2, R_3 und R_4 jeweils Wasserstoff sind.

8. 4(5)-(2,3-Dihydro-1H-inden-2-yl)-Imidazol.

9. 4(5)-(2,3-Dihydrobenzofuran-2-yl)-Imidazol.

10. 4(5)-(5-Brom-2,3-Dihydrobenzofuran-2-yl)-Imidazol.

11. 4(5)-(2,3-Dihydro-2-Ethyl-5-Methyl-1H-inden-2-yl)-Imidazol.

12. 4(5)-(2-Ethyl-1,2,3,4-Tetrahydronaphth-2-yl)-Imidazol.

13. 4(5)-(2,3-Dihydro-2-Ethyl-1-Methyl-1H-inden-2-yl)-Imidazol.

14. 4(5)-(2,3-Dihydro-2-n-Propyl-1H-inden-2-yl)-Imidazol.

15. 4(5)-(2,3-Dihydro-4-Methyl-1H-inden-2-yl)-Imidazol.

16. 4(5)-(2,3-Dihydro-5-Methyl-1H-inden-2-yl)-Imidazol.

17. 4(5)-(2,3-Dihydro-1-Methyl-1H-inden-2-yl)-Imidazol.

18. 4(5)-(2,3-Dihydro-1,4-Dimethyl-1H-inden-2-yl)-Imidazol.

19. 4(5)-(2,3-Dihydro-1,6-Dimethyl-1H-inden-2-yl)-Imidazol.

20. 4(5)-(5-Chlor-2,3-Dihydro-1H-inden-2-yl)-Imidazol.

21. 4(5)-(5-Brom-2,3-Dihydro-1H-inden-2-yl)-Imidazol.

22. 4(5)-(2,3-Dihydro-1-Hydroxy-1H-inden-2-yl)-Imidazol.

23. 4(5)-(2,3-Dihydro-2-Methyl-1H-inden-2-yl)-Imidazol.

24. 4(5)-(4-Chlor-2,3-Dihydro-1H-inden-2-yl)-Imidazol.

25. 4(5)-(4-Brom-2,3-Dihydro-1H-inden-2-yl)-Imidazol.

26. 4(5)-(2,3-Dihydro-2-Ethyl-1H-inden-2-yl)-Imidazol.

27. 4(5)-(2,3-Dihydro-2-n-Butyl-1H-inden-2-yl)-Imidazol.


28. 4(5)-(2,3-Dihydro-2,5-Dimethyl-1H-inden-2-yl)-Imidazol.

29. 4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)-Imidazol.


30. 4(5)-(2,3-Dihydro-2-Ethyl-1-Hydroxy-1H-inden-2-yl)-Imidazol.

31. Verfahren zur Herstellung eines Imidazols nach Anspruch 1, wobei R_1 Wasserstoff ist und R_3 und R_4 die in Anspruch 1 angegebene Bedeutung haben, und R_2 Wasserstoff, Methyl oder Ethyl ist, bei welchem

a) eine Verbindung der allgemeinen Formel:




halogeniert wird, wobei R_2, R_3 und R_4 die in Anspruch 1 angegebene Bedeutung haben, wobei sich ein Produkt der allgemeinen Formel:



ergibt, bei welchem Hal Cl oder Br ist, und


b) bei welchem das Produkt mit Formamid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, und bei welchem

c) dieses letzte Produkt katalytisch zu einer Verbindung nach Anspruch 1 hydriert wird.

32. Verfahren zur herstellung einer Verbindung nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel:




wobei R_5, R_6, R_7 und R_8 jeweils Wasserstoff, eine Hydroxylgruppe, ein Halogen, eine Aminogruppe oder ein —O— Alkyl mit 1 bis 7 Kohlenstoffatomen, oder




ist (wobei R_9 für ein Alkyl mit 1 bis 7 Kohlenstoffatomen oder Aryl mit 6 bis 10 Kohlenstoffatomen steht, und wobei R_5 und R_7 bzw. R_6 und R_8 jeweils zur Bildung einer Ketogruppe verbunden werden können, mit Formamid zu einer Verbindung der allgemeinen Formel (I) nach Anspruch 1 umgesetzt wird.

33. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, bei welchem R_3 ein Halogen und R_4 Wasserstoff ist, bzw. R_3 und R_4 jeweils beide Halogenatome darstellen, bei welchem eine Verbindung der allgemeinen Formel:




zu einer Verbindung nach Anspruch 1 halogeniert wird.


34. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, bei welchem R_1 Wasserstoff ist, R_3, R_4 und X die jeweils in Anspruch 1 angegebene Bedeutung haben, und R_2 Wasserstoff, Methyl oder Ethyl ist, bei welchem eine Verbindung der allgemeinen Formel:



zu einer Verbindung der allgemeinen Formel:




bromiert wird, welche zur Herstellung einer Verbindung der allgemeinen Formel:




mit Formamid umgesetzt wird, welche zu einer Verbindung der allgemeinen Formel (I) hydriert wird.


35. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel:




wobei R eine Benzylgruppe ist, mit Thionylchlorid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die mit Natriumzyanid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die ihrerseits zu einer Verbindung der allgemeinen Formel:




in alkalischer Lösung hydrolysiert wird, welche mit Polyphosphonsäure zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die entweder
(a) in Gegenwart von Palladium auf Kohlenstoff als Katalysator zu einer Verbindung der allgemeinen Formel:




hydriert wird, die mit $NaBH_4$ zu einer Verbindung der allgemeinen Formel:



reduziert wird, oder
(b) mit $NaBH_4$ zu einer Verbindung der allgemeinen Formel:



reduziert wird, die in Gegenwart von Palladium auf Kohlenstoff zu Verbindung der allgemeinen Formel:



hydriert wird.


* C L M S *

36. Pharmazeutisch verträgliche Zusammensetzung, die ein substituiertes Imidazol nach einem der Ansprüche 1 bis 30 in Verbindung mit einem verträglichen pharmazeutisch vertretbaren Träger enthält.

37. Imidazolderivat nach einem der Ansprüche 1 bis 30 bzw. ein nicht-toxisches saures Additionssalz zur Verwendung als α_2-Antagonist zu Behandlungszwecken.


Patentansprüche für den Vertragsstaat: AT

1. Verfahren zur Herstellung eines substituierten Imidazols der allgemeinen Formel:




(I)


und von dessen nicht-toxischen sauren Additionssalzen, wobei
x —CH_2—, —CH_2CH_2— oder —O— ist, R_1 Wasserstoff, ein Alkyl mit 1 bis 4 Kohlenstoffatomen, ein Alkenyl mit 2 bis 4 Kohlenstoffatomen, OCH_3 oder OCH_2CH_3 ist, R_2 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder OH ist, R_3 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder Hal ist, R_4 Wasserstoff, CH_3, CH_2CH_3, OCH_3 oder Hal ist, und Hal für ein Halogen steht, bei welchem eine Verbindung der allgemeinen Formel:



halogeniert wird, wobei R_2, R_3 und R_4 dieselbe Bedeutung wie oben haben, wobei sich ein Produkt der allgemeinen Formel:




ergibt, wobei Hal Cl oder Br ist, und bei welchem das Produkt mit Formamid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, und bei welchem dieses letzte Produkt katalytisch zu einer Verbindung der allgemeinen Formel (I) hydriert wird, wobei R_1 Wasserstoff ist, R_3 und R_4 die vorstehende Bedeutung haben, und R_2 Wasserstoff, Methyl oder Ethyl ist.

2. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel:




wobei R_5, R_6, R_7 und R_8 jeweils Wasserstoff, eine Hydroxylgruppe, ein Halogen, eine Aminogruppe oder ein —O— Alkyl mit 1 bis 7 Kohlenstoffatomen, oder




ist (wobei R_9 für ein Alkyl mit 1 bis 7 Kohlenstoffatomen oder Aryl mit 6 bis 10 Kohlenstoffatomen steht, und wobei R_5 und R_7 bzw. R_6 und R_8 jeweils zur Bildung einer Ketogruppe verbunden werden können, mit Formamid zu einer Verbindung der allgemeinen Formel (I) nach Anspruch 1 umgesetzt wird.

3. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem R_3 ein Halogen und R_4 Wasserstoff ist, bzw. R_3 und R_4 jeweils beide Halogenatome darstellen, bei welchem eine Verbindung der allgemeinen Formel:




zu einer Verbindung der genannten allgemeinen Formel (I) halogeniert wird.


4. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem R_1 Wasserstoff ist, R_3, R_4 und X die jeweils angegebene Bedeutung haben, und R_2 Wasserstoff, Methyl oder Ethyl ist, bei welchem eine Verbindung der allgemeinen Formel:



zu einer Verbindung der allgemeinen Formel:




bromiert wird, welche zur Herstellung einer Verbindung der allgemeinen Formel:




mit Formamid umgesetzt wird, welche zu einer Verbindung der genannten Art hydriert wird.


5. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel:




wobei R eine Benzylgruppe ist, mit Thionylchlorid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die mit Natriumzyanid zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die ihrerseits zu einer Verbindung der allgemeinen Formel:




in alkalischer Lösung hydrolysiert wird, welche mit Polyphosphonsäure zu einer Verbindung der allgemeinen Formel:




umgesetzt wird, die entweder (a) in Gegenwart von Palladium auf Kohlenstoff als Katalysator zu einer Verbindung der allgemeinen Formel:




hydriert wird, die mit $NaBH_4$ zu einer Verbindung der allgemeinen Formel:



reduziert wird, oder (b) mit $NaBH_4$ zu einer Verbindung der allgemeinen Formel:




reduziert wird, die in Gegenwart von Palladium auf Kohlenstoff zu Verbindung der allgemeinen Formel:




hydriert wird.


6. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel




halogeniert und mit Formamid umgesetzt wird, wobei sich eine Verbindung der allgemeinen Formel:




egibt, die entweder (a) in Gegenwart von Palladium auf Kohlenstoff zu einer Verbindung der allgemeinen Formel:



hydriert oder (b) mit $NaBH_4$ zu einem Produkt der allgemeinen Formel:




umgesetzt und anschließend in Gegenwart von Palladium auf Kohlenstoff zu einer Verbindung der allgemeinen Formel:




hydriert wird.


7. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (I) nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel:



halogeniert und mit Formamid zu einer Verbindung der allgemeinen Formel:



umgesetzt wird, die anschließend mit Pd/C zu einer Verbindung der allgemeinen Formel:




hydriert wird.

8. Verfahren nach einem der Ansprüche 1 bis 7, bei welchem das erhaltene Produkt in ein nicht-toxisches saures Additionssalz übergeführt wird.

Revendications pour les Etats contractants: BE CH DE FR GB IT LI LU NL SE

1. Imidazoles substitués de formule



(I)

et leurs sels d'addition d'acide non toxiques, dans lesquels X est —CH_2—, —CH_2CH_2— ou —O—, R_1 est H, un groupe alkyle de 1 à 4 atomes de carbone, alcényle de 2 à 4 atomes de carbone, OCH_3 ou OCH_2CH_3; R_2 est H, CH_3, CH_2CH_3, OCH_3 ou OH, R_3 est H, CH_3, CH_2CH_3, OCH_3 ou Hal et R_4 est H, CH_3, CH_2CH_3, OCH_3 ou Hal, et Hal est un halogène.

2. Imidazoles substitués selon la revendication 1, dans lesquels X est —CH_2—.

3. Imidazoles substitués selon la revendication 1, dans lesquels X est —CH_2CH_2—.

4. Imidazoles substitués selon la revendication 1, dans lesquels X est —O—.

* C L M S *

5. Imidazole substitués selon la revendication 1, dans lequel R_1 est un hydrogène, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3.

6. Imidazole substitués selon la revendication 1, dans lequel R_1 est un hydrogène, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 et X est CH_2.

7. Imidazoles substitués selon la revendication 1, dans lesquels R_1 est un hydrogène, CH_3, CH_2CH_3, OCH_3, OCH_2CH_3 et X est CH_2 et R_2, R_3 et R_4 sont des atomes d'hydrogène.

8. 4(5)-(2,3-Dihydro-1H-indène-2-yl)imidazole.

9. 4(5)-(2,3-Dihydrobenzofuranne-2-yl)imidazole.

10. 4(5)-(5-Bromo-2,3-dihydrobenzofuranne-2-yl)imidazole.

11. 4(5)-(2,3-Dihydro-2-éthyl-5-méthyl-1H-indène-2-yl)imidazole.

12. 4(5)-(2-Ethyl-1,2,3,4-tétrahydronaphtyl-2)imidazole.

13. 4(5)-(2,3-Dihydro-2-éthyl-1-méthyl-1H-indène-2-yl)imidazole.

14. 4(5)-(2,3-Dihydro-2-n-propyl-1H-indène-2-yl)imidazole.

15. 4(5)-(2,3-Dihydro-4-méthyl-1H-indène-2-yl)imidazole.

16. 4(5)-(2,3-Dihydro-5-méthyl-1H-indène-2-yl)-imidazole.

17. 4(5)-(2,3-Dihydro-1-méthyl-1H-indène-2-yl)imidazole.

18. 4(5)-(2,3-Dihydro-1,4-diméthyl-1H-indène-2-yl)imidazole.

19. 4(5)-(2,3-Dihydro-1,6-diméthyl-1H-indène-2-yl)imidazole.

20. 4(5)-(5-Chloro-2,3-dihydro-1H-indène-2-yl)imidazole.

21. 4(5)-(5-Bromo-2,3-dihydro-1H-indène-2-yl)imidazole.

22. 4(5)-(2,3-Dihydro-1-hydroxy-1H-indène-2-yl)imidazole.

23. 4(5)-(2,3-Dihydro-2-méthyl-1H-indène-2-yl)imidazole.

24. 4(5)-(4-Chloro-2,3-dihydro-1H-indène-2-yl)imidazole.

25. 4(5)-(4-Bromo-2,3-dihydro--1H-indène-2-yl)imidazole.

26. 4(5)-(2,3-Dihydro-2-éthyl-1H-indène-2-yl)imidazole.

27. 4(5)-(2,3-Dihydro-2-n-butyl-1H-indène-2-yl)imidazole.


28. 4(5)-(2,3-Dihydro-2,5-diméthyl-1H-indène-2-yl)imidazole.

29. 4(5)-(1,2,3,4-Tétrahydronaphtyl-2)imidazole.


30. 4(5)-(2,3-Dihydro-2-éthyl-1-hydroxy-1H-indène-2-yl)imidazole.

31. Procédé de préparation d'un imidazole selon la revendication 1, dans lequel R_1 est un hydrogène et R_3 et R_4 sont tels que définis dans la revendication 1 et R_2 est un hydrogène, un groupe méthyle ou éthyle, qui comprend:

a) l'halogénation d'un composé de formule




dans laquelle R_2, R_3 et R_4 snt tels que définis dans la revendication 1, pour donner un produit de formule




dans laquelle Hal est Cl ou Br

b) la réaction de ce produit avec du formamide pour donner un composé de formule




c) qui est ensuite catalytiquement hydrogéné pour donner un composé selon la revendication 1.

32. Procédé de préparation d'un composé selon la revendication 1, qui comprend la réaction d'un composé de formule




dans laquelle R_5, R_6, R_7 et R_8 sont chacun un atome d'hydrogène, un groupe hydroxy, halogéno, amino, —O—alkyle contenant 1 à 7 atomes de carbone, ou




(formule dans laquelle R_9 est un groupe alkyle de 1 à 7 atomes de carbone ou aryle de 6 à 10 atomes de carbone); et dans laquelle R_5 et R_7 peuvent être combinés pour former un groupe céto, ou R_6 et R_8 peuvent être combinés pour former un groupe céto, avec du formamide pour obtenir un composé de formule (I) selon la revendication 1.

33. Procédé de préparation d'un composé d'un composé selon la revendication 1, dans lequel R_3 est un halogène et R_4 est H, ou R_3 et R_4 sont tous deux des atomes d'halogène, qui comprend: l'halogénation d'un composé de formule




pour donner un composé seon la revendication 1.


34. Procédé de préparation d'un composé selon la revendication 1, dans lequel R_1 est un hydrogène, R_3, R_4 et X sont tels que définis dans la revendication 1 et R_2 est un hydrogène, un groupe méthyle ou éthyle, qui comprend la bromation d'un composé de formule



pour donner un composé de formule




que l'on fait réagir avec du formamide pour produire un composé de formule




qui est hydrogéné pour donner un composé de formule (I).


35. Procédé de préparation d'un composé selon la revendication 1, qui comprend la réaction d'un composé de formule




dans laquelle R est un groupe benzyle, avec du chlorure de thionyle pour donner un composé de formule:




que l'on fait réagir avec du cyanure de sodium pour obtenir un composé de formule:




qui est hydrolysé en solution alcaline pour donner un composé de formule:




que l'on fait réagir avec de l'acide polyphosphorique pour obtenir un composé de formule:




qui est ou bien
(a) hydrogéné en présence de palladium sur carbone comme catalyseur pour donner un composé de formule:




qui est réduit avec $NaBH_4$ pour donner un composé de formule:



ou bien
(b) réduit avec $NaBH_4$ pour donner un composé de formule:



qui est hydrogéné en présence de palladium sur carbone pour donner un composé de formule:




36. Composition pharmaceutique comprenant un imidazole substitué selon l'une quelconque des revendications 1 à 30 en association avec un véhicule compatible, pharmaceutiquement acceptable.

37. Dérivé imidazole selon l'une quelconque des revendications 1 à 30, ou sel d'addition d'acide non toxique, utilisable en thérapeutique comme antagoniste des récepteurs α_2.


Revendications pour l'Etat Contractant: AT

1. Procédé de préparation d'un imidazole substitué de formule




(I)


et de ses sels d'addition d'acide non toxiques, formule dans laquelle
X est —CH_2—, —CH_2CH_2— ou —O—, R_1 est H, un groupe alkyle de 1 à 4 atomes de carbone, alcényle de 2 à 4 atomes de carbone, OCH_3 ou OCH_2CH_3; R_2 est H, CH_3, CH_2CH_3, OCH_3 ou OH, R_3 est H, CH_3, CH_2CH_3, OCH_3 ou Hal et R_4 est H, CH_3, CH_2CH_3, OCH_3 ou Hal, et Hal est un halogène, qui comprend l'halogènation d'un composé de formule



dans laquelle R_2, R_3 et R_4 sont tels qu définis ci-dessus, pour donner un produit de formule




dans laquelle Hal est Cl ou Br, la réaction de ce produit avec du formamide pour donner un composé de formule




et l'hydrogénation catalytique de ce dernier pour donner un composé de formule (I), dans laquelle R_1 est un hydrogène, R_3 et R_4 sont tels que définis ci-dessus et R_2 est un hydrogène, un groupe méthyle ou éthyle.

2. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, qui comprend la réaction d'un composé de formule




dans laquelle R_5, R_6, R_7 et R_8 sont chacun un atome d'hydrogène, un groupe hydroxy, halogéno, amino, —O—alkyle contenant 1 à 7 atomes de carbone, ou



(formule dans laquelle R_9 est un groupe alkyle de 1 à 7 atomes de carbone ou aryle de 6 à 10 atomes de carbone); et dans laquelle R_5 et R_6 peuvent être combinés pour former un groupe céto, ou R_6 et R_8 peuvent être combinés pour former un groupe céto, avec du formamide pour obtenir un composé de formule (I) selon la revendication 1.

3. Procédé de préparation d'un composé d'un composé de formule I tel que défini dans la revendication 1, dans lequel R_3 est un halogène et R_4 est H, ou R_3 et R_4 sont tous deux des atomes d'halogène, qui comprend l'halogénation d'un composé de formule




pour donner un composé de formule I tel que défini ci-dessus.


4. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, dans lequel R_1 est un hydrogène, R_3, R_4 et X sont tels que définis ci-dessus et R_2 est un hydrogène, un groupe méthyle

* C L M S *


ou éthyle, qui comprend la bromation d'un composé de formule



pour donner un composé de formule




que l'on fait réagir avec du formamide pour produire un composé de formule




qui est hydrogéné pour donner un composé tel que défini ci-dessus.


5. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, qui comprend la réaction d'un compose de formule




dans laquelle R est un groupe benzyle, avec du chlorure de thionyle pour donner un composé de formule:




que l'on fait réagir avec du cyanure de sodium pour obtenir un composé de formule:




qui est hydrolysé en solution alcaline pour donner un composé de formule:




que l'on fait réagir avec de l'acide polyphosphorique pour obtenir un composé de formule:




qui est ou bien
(a) hydrogéné en présence de palladium sur carbone comme catalyseur pour donner un composé de formule:




qui est réduit avec $NaBH_4$ pour donner un composé de formule:




ou bien
(b) réduit avec $NaBH_4$ pour donner un composé de formule:




qui est hydrogéné en présence de palladium sur carbone pour donner un composé de formule:




6. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, qui comprend l'halogénation et la réaction avec du formamide d'un composé de formule




pour donner un composé de formule




qui est ou bien (a) hydrogéné en présence de palladium sur carbone pour donner un commposé de formule




ou bien (b) mis à réagir avec $NaBH_4$ pour donner un produit de formule



puis hydrogéné en présence de palladium sur carbone pour donner un composé de formule




7. Procédé de préparation d'un composé de formule I tel que défini dans la revendication 1, qui comprend l'halogénation et la réaction avec un formamide d'un composé de formule




* C L M S *

pour donner un composé de formule



qui est hydrogéné avec Pd/C pour donner un composé de formule



8. Procédé selon l'une quelconque des revendications 1 à 7, dans lequel le produit obtenu est transformé en un sel d'addition d'acide non toxique.